Compare WINA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | NBTX |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2006 | 2018 |
| Metric | WINA | NBTX |
|---|---|---|
| Price | $379.55 | $36.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 31.1K | ★ 65.0K |
| Earning Date | 04-15-2026 | 03-31-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ 3.76 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $86,055,700.00 | N/A |
| Revenue This Year | $5.55 | $58.17 |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | $150.28 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $338.18 | $4.29 |
| 52 Week High | $526.81 | $57.14 |
| Indicator | WINA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 44.60 |
| Support Level | $358.01 | $29.64 |
| Resistance Level | $393.93 | $41.89 |
| Average True Range (ATR) | 13.46 | 2.57 |
| MACD | 3.44 | -1.44 |
| Stochastic Oscillator | 74.92 | 13.62 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment, including Franchising, and one non-reportable segment, Leasing. The franchising segment franchises value-oriented retail stores that buy, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes the middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.